103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
SB2089

 

Introduced 2/9/2023, by Sen. Patrick J. Joyce

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/204  from Ch. 56 1/2, par. 1204
720 ILCS 570/401  from Ch. 56 1/2, par. 1401

    Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine.


LRB103 27669 RLC 57233 b

 

 

A BILL FOR

 

SB2089LRB103 27669 RLC 57233 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 204 and 401 as follows:
 
6    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
7    Sec. 204. (a) The controlled substances listed in this
8Section are included in Schedule I.
9    (b) Unless specifically excepted or unless listed in
10another schedule, any of the following opiates, including
11their isomers, esters, ethers, salts, and salts of isomers,
12esters, and ethers, whenever the existence of such isomers,
13esters, ethers and salts is possible within the specific
14chemical designation:
15        (1) Acetylmethadol;
16        (1.1) Acetyl-alpha-methylfentanyl
17    (N-[1-(1-methyl-2-phenethyl)-
18    4-piperidinyl]-N-phenylacetamide);
19        (2) Allylprodine;
20        (3) Alphacetylmethadol, except
21    levo-alphacetylmethadol (also known as levo-alpha-
22    acetylmethadol, levomethadyl acetate, or LAAM);
23        (4) Alphameprodine;

 

 

SB2089- 2 -LRB103 27669 RLC 57233 b

1        (5) Alphamethadol;
2        (6) Alpha-methylfentanyl
3    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
5    propanilido) piperidine;
6        (6.1) Alpha-methylthiofentanyl
7    (N-[1-methyl-2-(2-thienyl)ethyl-
8    4-piperidinyl]-N-phenylpropanamide);
9        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10        (7.1) PEPAP
11    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
12        (8) Benzethidine;
13        (9) Betacetylmethadol;
14        (9.1) Beta-hydroxyfentanyl
15    (N-[1-(2-hydroxy-2-phenethyl)-
16    4-piperidinyl]-N-phenylpropanamide);
17        (10) Betameprodine;
18        (11) Betamethadol;
19        (12) Betaprodine;
20        (13) Clonitazene;
21        (14) Dextromoramide;
22        (15) Diampromide;
23        (16) Diethylthiambutene;
24        (17) Difenoxin;
25        (18) Dimenoxadol;
26        (19) Dimepheptanol;

 

 

SB2089- 3 -LRB103 27669 RLC 57233 b

1        (20) Dimethylthiambutene;
2        (21) Dioxaphetylbutyrate;
3        (22) Dipipanone;
4        (23) Ethylmethylthiambutene;
5        (24) Etonitazene;
6        (25) Etoxeridine;
7        (26) Furethidine;
8        (27) Hydroxpethidine;
9        (28) Ketobemidone;
10        (29) Levomoramide;
11        (30) Levophenacylmorphan;
12        (31) 3-Methylfentanyl
13    (N-[3-methyl-1-(2-phenylethyl)-
14    4-piperidyl]-N-phenylpropanamide);
15        (31.1) 3-Methylthiofentanyl
16    (N-[(3-methyl-1-(2-thienyl)ethyl-
17    4-piperidinyl]-N-phenylpropanamide);
18        (32) Morpheridine;
19        (33) Noracymethadol;
20        (34) Norlevorphanol;
21        (35) Normethadone;
22        (36) Norpipanone;
23        (36.1) Para-fluorofentanyl
24    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
25    4-piperidinyl]propanamide);
26        (37) Phenadoxone;

 

 

SB2089- 4 -LRB103 27669 RLC 57233 b

1        (38) Phenampromide;
2        (39) Phenomorphan;
3        (40) Phenoperidine;
4        (41) Piritramide;
5        (42) Proheptazine;
6        (43) Properidine;
7        (44) Propiram;
8        (45) Racemoramide;
9        (45.1) Thiofentanyl
10    (N-phenyl-N-[1-(2-thienyl)ethyl-
11    4-piperidinyl]-propanamide);
12        (46) Tilidine;
13        (47) Trimeperidine;
14        (48) Beta-hydroxy-3-methylfentanyl (other name:
15    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
16    N-phenylpropanamide);
17        (49) Furanyl fentanyl (FU-F);
18        (50) Butyryl fentanyl;
19        (51) Valeryl fentanyl;
20        (52) Acetyl fentanyl;
21        (53) Beta-hydroxy-thiofentanyl;
22        (54) 3,4-dichloro-N-[2-
23    (dimethylamino)cyclohexyl]-N-
24    methylbenzamide (U-47700); 
25        (55) 4-chloro-N-[1-[2-
26    (4-nitrophenyl)ethyl]-2-piperidinylidene]-

 

 

SB2089- 5 -LRB103 27669 RLC 57233 b

1    benzenesulfonamide (W-18); 
2        (56) 4-chloro-N-[1-(2-phenylethyl)
3    -2-piperidinylidene]-benzenesulfonamide (W-15); 
4        (57) acrylfentanyl (acryloylfentanyl). 
5    (c) Unless specifically excepted or unless listed in
6another schedule, any of the following opium derivatives, its
7salts, isomers and salts of isomers, whenever the existence of
8such salts, isomers and salts of isomers is possible within
9the specific chemical designation:
10        (1) Acetorphine;
11        (2) Acetyldihydrocodeine;
12        (3) Benzylmorphine;
13        (4) Codeine methylbromide;
14        (5) Codeine-N-Oxide;
15        (6) Cyprenorphine;
16        (7) Desomorphine;
17        (8) Diacetyldihydromorphine (Dihydroheroin);
18        (9) Dihydromorphine;
19        (10) Drotebanol;
20        (11) Etorphine (except hydrochloride salt);
21        (12) Heroin;
22        (13) Hydromorphinol;
23        (14) Methyldesorphine;
24        (15) Methyldihydromorphine;
25        (16) Morphine methylbromide;
26        (17) Morphine methylsulfonate;

 

 

SB2089- 6 -LRB103 27669 RLC 57233 b

1        (18) Morphine-N-Oxide;
2        (19) Myrophine;
3        (20) Nicocodeine;
4        (21) Nicomorphine;
5        (22) Normorphine;
6        (23) Pholcodine;
7        (24) Thebacon.
8    (d) Unless specifically excepted or unless listed in
9another schedule, any material, compound, mixture, or
10preparation which contains any quantity of the following
11hallucinogenic substances, or which contains any of its salts,
12isomers and salts of isomers, whenever the existence of such
13salts, isomers, and salts of isomers is possible within the
14specific chemical designation (for the purposes of this
15paragraph only, the term "isomer" includes the optical,
16position and geometric isomers):
17        (1) 3,4-methylenedioxyamphetamine
18    (alpha-methyl,3,4-methylenedioxyphenethylamine,
19    methylenedioxyamphetamine, MDA);
20        (1.1) Alpha-ethyltryptamine
21    (some trade or other names: etryptamine;
22    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
23    3-(2-aminobutyl)indole; a-ET; and AET);
24        (2) 3,4-methylenedioxymethamphetamine (MDMA);
25        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
26    (also known as: N-ethyl-alpha-methyl-

 

 

SB2089- 7 -LRB103 27669 RLC 57233 b

1    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
2    and MDEA);
3        (2.2) N-Benzylpiperazine (BZP);
4        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
5        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
6        (4) 3,4,5-trimethoxyamphetamine (TMA);
7        (5) (Blank);
8        (6) Diethyltryptamine (DET);
9        (7) Dimethyltryptamine (DMT);
10        (7.1) 5-Methoxy-diallyltryptamine;
11        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
12        (9) Ibogaine  (some trade and other names:
13    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
14    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
15    indole; Tabernanthe iboga);
16        (10) Lysergic acid diethylamide;
17        (10.1) Salvinorin A;
18        (10.5) Salvia divinorum (meaning all parts of the
19    plant presently classified botanically as Salvia
20    divinorum, whether growing or not, the seeds thereof, any
21    extract from any part of that plant, and every compound,
22    manufacture, salts, isomers, and salts of isomers whenever
23    the existence of such salts, isomers, and salts of isomers
24    is possible within the specific chemical designation,
25    derivative, mixture, or preparation of that plant, its
26    seeds or extracts);

 

 

SB2089- 8 -LRB103 27669 RLC 57233 b

1        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
2        (12) Peyote (meaning all parts of the plant presently
3    classified botanically as Lophophora williamsii Lemaire,
4    whether growing or not, the seeds thereof, any extract
5    from any part of that plant, and every compound,
6    manufacture, salts, derivative, mixture, or preparation of
7    that plant, its seeds or extracts);
8        (13) N-ethyl-3-piperidyl benzilate (JB 318);
9        (14) N-methyl-3-piperidyl benzilate;
10        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
11    (also known as N-hydroxy-alpha-methyl-
12    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
13        (15) Parahexyl; some trade or other names:
14    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
15    dibenzo (b,d) pyran; Synhexyl;
16        (16) Psilocybin;
17        (17) Psilocyn;
18        (18) Alpha-methyltryptamine (AMT);
19        (19) 2,5-dimethoxyamphetamine
20    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
21        (20) 4-bromo-2,5-dimethoxyamphetamine
22    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
23    4-bromo-2,5-DMA);
24        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
25    Some trade or other names: 2-(4-bromo-
26    2,5-dimethoxyphenyl)-1-aminoethane;

 

 

SB2089- 9 -LRB103 27669 RLC 57233 b

1    alpha-desmethyl DOB, 2CB, Nexus;
2        (21) 4-methoxyamphetamine
3    (4-methoxy-alpha-methylphenethylamine;
4    paramethoxyamphetamine; PMA);
5        (22) (Blank);
6        (23) Ethylamine analog of phencyclidine.
7    Some trade or other names:
8    N-ethyl-1-phenylcyclohexylamine,
9    (1-phenylcyclohexyl) ethylamine,
10    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
11        (24) Pyrrolidine analog of phencyclidine. Some trade
12    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
13    PHP;
14        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
15        (26) 2,5-dimethoxy-4-ethylamphetamine
16    (another name: DOET);
17        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
18    (another name: TCPy);
19        (28) (Blank);
20        (29) Thiophene analog of phencyclidine (some trade
21    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
22    2-thienyl analog of phencyclidine; TPCP; TCP);
23        (29.1) Benzothiophene analog of phencyclidine. Some
24    trade or other names: BTCP or benocyclidine;
25        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
26        (30) Bufotenine (some trade or other names:

 

 

SB2089- 10 -LRB103 27669 RLC 57233 b

1    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
2    3-(2-dimethylaminoethyl)-5-indolol;
3    5-hydroxy-N,N-dimethyltryptamine;
4    N,N-dimethylserotonin; mappine);
5        (31) (Blank);  
6        (32) (Blank);  
7        (33) (Blank);  
8        (34) (Blank); 
9        (34.5) (Blank);  
10        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
11    (2-methyloctan-2-yl)-6a,7, 
12    10,10a-tetrahydrobenzo[c]chromen-1-ol
13    Some trade or other names: HU-210; 
14        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
15    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
16    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
17    salts, and salts of isomers; Some trade or other  
18    names: HU-210, Dexanabinol; 
19        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
20    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
21    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
22    Some trade or other names: HU-211;
23        (37) (Blank);
24        (38) (Blank);
25        (39) (Blank);
26        (40) (Blank);

 

 

SB2089- 11 -LRB103 27669 RLC 57233 b

1        (41) (Blank);
2        (42) Any compound structurally derived from
3    3-(1-naphthoyl)indole or
4    1H-indol-3-yl-(1-naphthyl)methane by substitution at the
5    nitrogen atom of the indole ring by alkyl, haloalkyl,
6    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl whether or not further substituted
9    in the indole ring to any extent, whether or not
10    substituted in the naphthyl ring to any extent. Examples
11    of this structural class include, but are not limited to,
12    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
13        (43) Any compound structurally derived from
14    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
15    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
16    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17    halide, 1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    in the pyrrole ring to any extent, whether or not
20    substituted in the naphthyl ring to any extent. Examples
21    of this structural class include, but are not limited to,
22    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
23        (44) Any compound structurally derived from
24    1-(1-naphthylmethyl)indene by substitution at the
25    3-position of the indene ring by alkyl, haloalkyl,
26    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

 

 

SB2089- 12 -LRB103 27669 RLC 57233 b

1    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2    2-(4-morpholinyl)ethyl whether or not further substituted
3    in the indene ring to any extent, whether or not
4    substituted in the naphthyl ring to any extent. Examples
5    of this structural class include, but are not limited to,
6    JWH-176;
7        (45) Any compound structurally derived from
8    3-phenylacetylindole by substitution at the nitrogen atom
9    of the indole ring with alkyl, haloalkyl, alkenyl,
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11    halide, 1-(N-methyl-2-piperidinyl)methyl, or
12    2-(4-morpholinyl)ethyl, whether or not further substituted
13    in the indole ring to any extent, whether or not
14    substituted in the phenyl ring to any extent. Examples of
15    this structural class include, but are not limited to,
16    JWH-167, JWH-250, JWH-251, and RCS-8;
17        (46) Any compound structurally derived from
18    2-(3-hydroxycyclohexyl)phenol by substitution at the
19    5-position of the phenolic ring by alkyl, haloalkyl,
20    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
21    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
22    2-(4-morpholinyl)ethyl, whether or not substituted in the
23    cyclohexyl ring to any extent. Examples of this structural
24    class include, but are not limited to, CP 47, 497 and its
25    C8 homologue (cannabicyclohexanol);
26        (46.1) Any compound structurally derived from

 

 

SB2089- 13 -LRB103 27669 RLC 57233 b

1    3-(benzoyl) indole with substitution at the nitrogen atom
2    of the indole ring by an alkyl, haloalkyl, alkenyl,
3    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4    halide, 1-(N-methyl-2-piperidinyl)methyl, or
5    2-(4-morpholinyl)ethyl group whether or not further
6    substituted in the indole ring to any extent and whether
7    or not substituted in the phenyl ring to any extent.
8    Examples of this structural class include, but are not
9    limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
10    48,098), and RCS-4;
11        (47) (Blank);
12        (48) (Blank);
13        (49) (Blank);
14        (50) (Blank);
15        (51) (Blank);
16        (52) (Blank);
17        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
18    Some trade or other names: 2C-T-7;
19        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
20    trade or other names: 2C-E;
21        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
22    trade or other names: 2C-D;
23        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
24    trade or other names: 2C-C;
25        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
26    or other names: 2C-I;

 

 

SB2089- 14 -LRB103 27669 RLC 57233 b

1        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
2    trade or other names: 2C-T-2;
3        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
4    Some trade or other names: 2C-T-4;
5        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
6    other names: 2C-H;
7        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
8    trade or other names: 2C-N;
9        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
10    trade or other names: 2C-P;
11        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
12    Some trade or other names: 2C-G;
13        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
14    phenethylamine referred to in subparagraphs (20.1), (53),
15    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
16    (53.8), (53.9), and (53.10) including, but not limited to,
17    25I-NBOMe and 25C-NBOMe;
18        (54) 5-Methoxy-N,N-diisopropyltryptamine;
19        (55) (Blank);
20        (56) (Blank);
21        (57) (Blank);
22        (58) (Blank);
23        (59) 3-cyclopropoylindole with substitution at the
24    nitrogen atom of the indole ring by alkyl, haloalkyl,
25    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
26    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB2089- 15 -LRB103 27669 RLC 57233 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the indole ring to any extent, whether or not
3    substituted on the cyclopropyl ring to any extent:
4    including, but not limited to, XLR11, UR144, FUB-144;
5        (60) 3-adamantoylindole with substitution at the
6    nitrogen atom of the indole ring by alkyl, haloalkyl,
7    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl, whether or not further substituted
10    on the indole ring to any extent, whether or not
11    substituted on the adamantyl ring to any extent:
12    including, but not limited to, AB-001;
13        (61) N-(adamantyl)-indole-3-carboxamide with
14    substitution at the nitrogen atom of the indole ring by
15    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16    cycloalkylethyl, aryl halide, alkyl aryl halide,
17    1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    on the indole ring to any extent, whether or not
20    substituted on the adamantyl ring to any extent:
21    including, but not limited to, APICA/2NE-1, STS-135;
22        (62) N-(adamantyl)-indazole-3-carboxamide with
23    substitution at a nitrogen atom of the indazole ring by
24    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25    cycloalkylethyl, aryl halide, alkyl aryl halide,
26    1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB2089- 16 -LRB103 27669 RLC 57233 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the indazole ring to any extent, whether or not
3    substituted on the adamantyl ring to any extent:
4    including, but not limited to, AKB48, 5F-AKB48;
5        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
6    with substitution at the nitrogen atom of the indole ring
7    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8    cycloalkylethyl, aryl halide, alkyl aryl halide,
9    1-(N-methyl-2-piperidinyl)methyl, or
10    2-(4-morpholinyl)ethyl, whether or not further substituted
11    on the indole ring to any extent, whether or not
12    substituted on the quinoline ring to any extent:
13    including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
14        (64) 3-(1-naphthoyl)indazole with substitution at the
15    nitrogen atom of the indazole ring by alkyl, haloalkyl,
16    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
17    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
18    2-(4-morpholinyl)ethyl, whether or not further substituted
19    on the indazole ring to any extent, whether or not
20    substituted on the naphthyl ring to any extent: including,
21    but not limited to, THJ-018, THJ-2201;
22        (65) 2-(1-naphthoyl)benzimidazole with substitution
23    at the nitrogen atom of the benzimidazole ring by alkyl,
24    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25    aryl halide, alkyl aryl halide,
26    1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB2089- 17 -LRB103 27669 RLC 57233 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the benzimidazole ring to any extent, whether or not
3    substituted on the naphthyl ring to any extent: including,
4    but not limited to, FUBIMINA;
5        (66)
6    N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
7    3-carboxamide with substitution on the nitrogen atom of
8    the indazole ring by alkyl, haloalkyl, alkenyl,
9    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10    halide, 1-(N-methyl-2-piperidinyl)methyl, or
11    2-(4-morpholinyl)ethyl, whether or not further substituted
12    on the indazole ring to any extent: including, but not
13    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
14        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
15    indazole-3-carboxamide with substitution on the nitrogen
16    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
17    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18    halide, 1-(N-methyl-2-piperidinyl)methyl, or
19    2-(4-morpholinyl)ethyl, whether or not further substituted
20    on the indazole ring to any extent: including, but not
21    limited to, ADB-PINACA, ADB-FUBINACA;
22        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
23    indole-3-carboxamide with substitution on the nitrogen
24    atom of the indole ring by alkyl, haloalkyl, alkenyl,
25    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26    halide, 1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB2089- 18 -LRB103 27669 RLC 57233 b

1    2-(4-morpholinyl)ethyl, whether or not further substituted
2    on the indole ring to any extent: including, but not
3    limited to, ADBICA, 5F-ADBICA;
4        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
5    3-carboxamide with substitution on the nitrogen atom of
6    the indole ring by alkyl, haloalkyl, alkenyl,
7    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8    halide, 1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl, whether or not further substituted
10    on the indole ring to any extent: including, but not
11    limited to, ABICA, 5F-ABICA;
12        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
13    methylbutanoate with substitution on the nitrogen atom of
14    the indazole ring by alkyl, haloalkyl, alkenyl,
15    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16    halide, 1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indazole ring to any extent: including, but not
19    limited to, AMB, 5F-AMB;
20        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
21    dimethylbutanoate with substitution on the nitrogen atom
22    of the indazole ring by alkyl, haloalkyl, alkenyl,
23    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24    halide, 1-(N-methyl-2-piperidinyl)methyl, or
25    2-(4-morpholinyl)ethyl, whether or not further substituted
26    on the indazole ring to any extent: including, but not

 

 

SB2089- 19 -LRB103 27669 RLC 57233 b

1    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
2        (72) Methyl 2-(1H-indole-3-carboxamido)-3-
3    methylbutanoate with substitution on the nitrogen atom of
4    the indole ring by alkyl, haloalkyl, alkenyl,
5    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6    halide, 1-(N-methyl-2-piperidinyl)methyl, or
7    2-(4-morpholinyl)ethyl, whether or not further substituted
8    on the indazole ring to any extent: including, but not
9    limited to, MMB018, MMB2201, and AMB-CHMICA;
10        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
11    dimethylbutanoate with substitution on the nitrogen atom
12    of the indole ring by alkyl, haloalkyl, alkenyl,
13    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14    halide, 1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the indazole ring to any extent: including, but not
17    limited to, MDMB-CHMICA;
18        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
19    indazole-3-carboxamide with substitution on the nitrogen
20    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
21    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22    halide, 1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    on the indazole ring to any     extent: including, but not
25    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
26        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-

 

 

SB2089- 20 -LRB103 27669 RLC 57233 b

1    3-carboxamide with substitution on the nitrogen atom of
2    the indole ring by alkyl, haloalkyl, alkenyl,
3    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4    halide, 1-(N-methyl-2-piperidinyl)methyl, or
5    2-(4-morpholinyl)ethyl, whether or not further substituted
6    on the indazole ring to any extent: including, but not
7    limited to, APP-PICA and 5-fluoro-APP-PICA;
8        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
9    4-AcO-DMT;
10        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
11    name 5-MeO-MIPT;
12        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
13        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
14        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
15        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
16    (4-HO-MiPT);
17        (82) Fluorophenylpiperazine;
18        (83) Methoxetamine;
19        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
20    ethcathinone).
21    (e) Unless specifically excepted or unless listed in
22another schedule, any material, compound, mixture, or
23preparation which contains any quantity of the following
24substances having a depressant effect on the central nervous
25system, including its salts, isomers, and salts of isomers
26whenever the existence of such salts, isomers, and salts of

 

 

SB2089- 21 -LRB103 27669 RLC 57233 b

1isomers is possible within the specific chemical designation:
2        (1) mecloqualone;
3        (2) methaqualone; and
4        (3) gamma hydroxybutyric acid; and
5        (4) xylazine.
6    (f) Unless specifically excepted or unless listed in
7another schedule, any material, compound, mixture, or
8preparation which contains any quantity of the following
9substances having a stimulant effect on the central nervous
10system, including its salts, isomers, and salts of isomers:
11        (1) Fenethylline;
12        (2) N-ethylamphetamine;
13        (3) Aminorex (some other names:
14    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
15    4-5-dihydro-5-phenyl-2-oxazolamine) and its
16    salts, optical isomers, and salts of optical isomers;
17        (4) Methcathinone (some other names:
18    2-methylamino-1-phenylpropan-1-one;
19    Ephedrone; 2-(methylamino)-propiophenone;
20    alpha-(methylamino)propiophenone; N-methylcathinone;
21    methycathinone; Monomethylpropion; UR 1431) and its
22    salts, optical isomers, and salts of optical isomers;
23        (5) Cathinone (some trade or other names:
24    2-aminopropiophenone; alpha-aminopropiophenone;
25    2-amino-1-phenyl-propanone; norephedrone);
26        (6) N,N-dimethylamphetamine (also known as:

 

 

SB2089- 22 -LRB103 27669 RLC 57233 b

1    N,N-alpha-trimethyl-benzeneethanamine;
2    N,N-alpha-trimethylphenethylamine);
3        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
4    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
5        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
6        (9) Halogenated amphetamines and
7    methamphetamines - any compound derived from either
8    amphetamine or methamphetamine through the substitution
9    of a halogen on the phenyl ring, including, but not
10    limited to, 2-fluoroamphetamine, 3-
11    fluoroamphetamine and 4-fluoroamphetamine; 
12        (10) Aminopropylbenzofuran (APB):
13    including 4-(2-Aminopropyl) benzofuran, 5-
14    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
15    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
16        (11) Aminopropyldihydrobenzofuran (APDB):
17    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
18    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
19    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
20    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
21        (12) Methylaminopropylbenzofuran
22    (MAPB): including 4-(2-methylaminopropyl)
23    benzofuran, 5-(2-methylaminopropyl)benzofuran,
24    6-(2-methylaminopropyl)benzofuran
25    and 7-(2-methylaminopropyl)benzofuran. 
26    (g) Temporary listing of substances subject to emergency

 

 

SB2089- 23 -LRB103 27669 RLC 57233 b

1scheduling. Any material, compound, mixture, or preparation
2that contains any quantity of the following substances:
3        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
4    (benzylfentanyl), its optical isomers, isomers, salts, and
5    salts of isomers;
6        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
7    phenylpropanamide (thenylfentanyl), its optical isomers,
8    salts, and salts of isomers.
9    (h) Synthetic cathinones. Unless specifically excepted,
10any chemical compound which is not approved by the United
11States Food and Drug Administration or, if approved, is not
12dispensed or possessed in accordance with State or federal
13law, not including bupropion, structurally derived from
142-aminopropan-1-one by substitution at the 1-position with
15either phenyl, naphthyl, or thiophene ring systems, whether or
16not the compound is further modified in one or more of the
17following ways:
18        (1) by substitution in the ring system to any extent
19    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
20    halide substituents, whether or not further substituted in
21    the ring system by one or more other univalent
22    substituents. Examples of this class include, but are not
23    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
24        (2) by substitution at the 3-position with an acyclic
25    alkyl substituent. Examples of this class include, but are
26    not limited to, 2-methylamino-1-phenylbutan-1-one

 

 

SB2089- 24 -LRB103 27669 RLC 57233 b

1    (buphedrone); or
2        (3) by substitution at the 2-amino nitrogen atom with
3    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
4    inclusion of the 2-amino nitrogen atom in a cyclic
5    structure. Examples of this class include, but are not
6    limited to, Dimethylcathinone, Ethcathinone, and
7    a-Pyrrolidinopropiophenone (a-PPP); or
8    Any other synthetic cathinone which is not approved by the
9United States Food and Drug Administration or, if approved, is
10not dispensed or possessed in accordance with State or federal
11law.
12    (i) Synthetic cannabinoids or piperazines. Any synthetic
13cannabinoid or piperazine which is not approved by the United
14States Food and Drug Administration or, if approved, which is
15not dispensed or possessed in accordance with State and
16federal law.
17(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
18100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
198-14-18.)
 
20    (720 ILCS 570/401)  (from Ch. 56 1/2, par. 1401)
21    Sec. 401. Manufacture or delivery, or possession with
22intent to manufacture or deliver, a controlled substance, a
23counterfeit substance, or controlled substance analog. Except
24as authorized by this Act, it is unlawful for any person
25knowingly to manufacture or deliver, or possess with intent to

 

 

SB2089- 25 -LRB103 27669 RLC 57233 b

1manufacture or deliver, a controlled substance other than
2methamphetamine and other than bath salts as defined in the
3Bath Salts Prohibition Act sold or offered for sale in a retail
4mercantile establishment as defined in Section 16-0.1 of the
5Criminal Code of 2012, a counterfeit substance, or a
6controlled substance analog. A violation of this Act with
7respect to each of the controlled substances listed herein
8constitutes a single and separate violation of this Act. For
9purposes of this Section, "controlled substance analog" or
10"analog" means a substance, other than a controlled substance,
11which is not approved by the United States Food and Drug
12Administration or, if approved, is not dispensed or possessed
13in accordance with State or federal law, and that has a
14chemical structure substantially similar to that of a
15controlled substance in Schedule I or II, or that was
16specifically designed to produce an effect substantially
17similar to that of a controlled substance in Schedule I or II.
18Examples of chemical classes in which controlled substance
19analogs are found include, but are not limited to, the
20following: phenethylamines, N-substituted piperidines,
21morphinans, ecgonines, quinazolinones, substituted indoles,
22and arylcycloalkylamines. For purposes of this Act, a
23controlled substance analog shall be treated in the same
24manner as the controlled substance to which it is
25substantially similar.
26    (a) Any person who violates this Section with respect to

 

 

SB2089- 26 -LRB103 27669 RLC 57233 b

1the following amounts of controlled or counterfeit substances
2or controlled substance analogs, notwithstanding any of the
3provisions of subsections (c), (d), (e), (f), (g) or (h) to the
4contrary, is guilty of a Class X felony and shall be sentenced
5to a term of imprisonment as provided in this subsection (a)
6and fined as provided in subsection (b):
7        (1)(A) not less than 6 years and not more than 30 years
8    with respect to 15 grams or more but less than 100 grams of
9    a substance containing heroin, or an analog thereof;
10        (B) not less than 9 years and not more than 40 years
11    with respect to 100 grams or more but less than 400 grams
12    of a substance containing heroin, or an analog thereof;
13        (C) not less than 12 years and not more than 50 years
14    with respect to 400 grams or more but less than 900 grams
15    of a substance containing heroin, or an analog thereof;
16        (D) not less than 15 years and not more than 60 years
17    with respect to 900 grams or more of any substance
18    containing heroin, or an analog thereof;
19        (1.5)(A) not less than 6 years and not more than 30
20    years with respect to 15 grams or more but less than 100
21    grams of a substance containing fentanyl or xylazine, or
22    an analog thereof;
23        (B) not less than 9 years and not more than 40 years
24    with respect to 100 grams or more but less than 400 grams
25    of a substance containing fentanyl or xylazine, or an
26    analog thereof;

 

 

SB2089- 27 -LRB103 27669 RLC 57233 b

1        (C) not less than 12 years and not more than 50 years
2    with respect to 400 grams or more but less than 900 grams
3    of a substance containing fentanyl or xylazine, or an
4    analog thereof;
5        (D) not less than 15 years and not more than 60 years
6    with respect to 900 grams or more of a substance
7    containing fentanyl or xylazine, or an analog thereof;
8        (2)(A) not less than 6 years and not more than 30 years
9    with respect to 15 grams or more but less than 100 grams of
10    a substance containing cocaine, or an analog thereof;
11        (B) not less than 9 years and not more than 40 years
12    with respect to 100 grams or more but less than 400 grams
13    of a substance containing cocaine, or an analog thereof;
14        (C) not less than 12 years and not more than 50 years
15    with respect to 400 grams or more but less than 900 grams
16    of a substance containing cocaine, or an analog thereof;
17        (D) not less than 15 years and not more than 60 years
18    with respect to 900 grams or more of any substance
19    containing cocaine, or an analog thereof;
20        (3)(A) not less than 6 years and not more than 30 years
21    with respect to 15 grams or more but less than 100 grams of
22    a substance containing morphine, or an analog thereof;
23        (B) not less than 9 years and not more than 40 years
24    with respect to 100 grams or more but less than 400 grams
25    of a substance containing morphine, or an analog thereof;
26        (C) not less than 12 years and not more than 50 years

 

 

SB2089- 28 -LRB103 27669 RLC 57233 b

1    with respect to 400 grams or more but less than 900 grams
2    of a substance containing morphine, or an analog thereof;
3        (D) not less than 15 years and not more than 60 years
4    with respect to 900 grams or more of a substance
5    containing morphine, or an analog thereof;
6        (4) 200 grams or more of any substance containing
7    peyote, or an analog thereof;
8        (5) 200 grams or more of any substance containing a
9    derivative of barbituric acid or any of the salts of a
10    derivative of barbituric acid, or an analog thereof;
11        (6) 200 grams or more of any substance containing
12    amphetamine or any salt of an optical isomer of
13    amphetamine, or an analog thereof;
14        (6.5) (blank);
15        (6.6) (blank);
16        (7)(A) not less than 6 years and not more than 30 years
17    with respect to: (i) 15 grams or more but less than 100
18    grams of a substance containing lysergic acid diethylamide
19    (LSD), or an analog thereof, or (ii) 15 or more objects or
20    15 or more segregated parts of an object or objects but
21    less than 200 objects or 200 segregated parts of an object
22    or objects containing in them or having upon them any
23    amounts of any substance containing lysergic acid
24    diethylamide (LSD), or an analog thereof;
25        (B) not less than 9 years and not more than 40 years
26    with respect to: (i) 100 grams or more but less than 400

 

 

SB2089- 29 -LRB103 27669 RLC 57233 b

1    grams of a substance containing lysergic acid diethylamide
2    (LSD), or an analog thereof, or (ii) 200 or more objects or
3    200 or more segregated parts of an object or objects but
4    less than 600 objects or less than 600 segregated parts of
5    an object or objects containing in them or having upon
6    them any amount of any substance containing lysergic acid
7    diethylamide (LSD), or an analog thereof;
8        (C) not less than 12 years and not more than 50 years
9    with respect to: (i) 400 grams or more but less than 900
10    grams of a substance containing lysergic acid diethylamide
11    (LSD), or an analog thereof, or (ii) 600 or more objects or
12    600 or more segregated parts of an object or objects but
13    less than 1500 objects or 1500 segregated parts of an
14    object or objects containing in them or having upon them
15    any amount of any substance containing lysergic acid
16    diethylamide (LSD), or an analog thereof;
17        (D) not less than 15 years and not more than 60 years
18    with respect to: (i) 900 grams or more of any substance
19    containing lysergic acid diethylamide (LSD), or an analog
20    thereof, or (ii) 1500 or more objects or 1500 or more
21    segregated parts of an object or objects containing in
22    them or having upon them any amount of a substance
23    containing lysergic acid diethylamide (LSD), or an analog
24    thereof;
25    (7.5)(A) not less than 6 years and not more than 30 years
26    with respect to: (i) 15 grams or more but less than 100

 

 

SB2089- 30 -LRB103 27669 RLC 57233 b

1    grams of a substance listed in paragraph (1), (2), (2.1),
2    (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
3    (26) of subsection (d) of Section 204, or an analog or
4    derivative thereof, or (ii) 15 or more pills, tablets,
5    caplets, capsules, or objects but less than 200 pills,
6    tablets, caplets, capsules, or objects containing in them
7    or having upon them any amounts of any substance listed in
8    paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
9    (20.1), (21), (25), or (26) of subsection (d) of Section
10    204, or an analog or derivative thereof;
11        (B) not less than 9 years and not more than 40 years
12    with respect to: (i) 100 grams or more but less than 400
13    grams of a substance listed in paragraph (1), (2), (2.1),
14    (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
15    (26) of subsection (d) of Section 204, or an analog or
16    derivative thereof, or (ii) 200 or more pills, tablets,
17    caplets, capsules, or objects but less than 600 pills,
18    tablets, caplets, capsules, or objects containing in them
19    or having upon them any amount of any substance listed in
20    paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
21    (20.1), (21), (25), or (26) of subsection (d) of Section
22    204, or an analog or derivative thereof;
23        (C) not less than 12 years and not more than 50 years
24    with respect to: (i) 400 grams or more but less than 900
25    grams of a substance listed in paragraph (1), (2), (2.1),
26    (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or

 

 

SB2089- 31 -LRB103 27669 RLC 57233 b

1    (26) of subsection (d) of Section 204, or an analog or
2    derivative thereof, or (ii) 600 or more pills, tablets,
3    caplets, capsules, or objects but less than 1,500 pills,
4    tablets, caplets, capsules, or objects containing in them
5    or having upon them any amount of any substance listed in
6    paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
7    (20.1), (21), (25), or (26) of subsection (d) of Section
8    204, or an analog or derivative thereof;
9        (D) not less than 15 years and not more than 60 years
10    with respect to: (i) 900 grams or more of any substance
11    listed in paragraph (1), (2), (2.1), (2.2), (3), (14.1),
12    (19), (20), (20.1), (21), (25), or (26) of subsection (d)
13    of Section 204, or an analog or derivative thereof, or
14    (ii) 1,500 or more pills, tablets, caplets, capsules, or
15    objects containing in them or having upon them any amount
16    of a substance listed in paragraph (1), (2), (2.1), (2.2),
17    (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
18    subsection (d) of Section 204, or an analog or derivative
19    thereof;
20        (8) 30 grams or more of any substance containing
21    pentazocine or any of the salts, isomers and salts of
22    isomers of pentazocine, or an analog thereof;
23        (9) 30 grams or more of any substance containing
24    methaqualone or any of the salts, isomers and salts of
25    isomers of methaqualone, or an analog thereof;
26        (10) 30 grams or more of any substance containing

 

 

SB2089- 32 -LRB103 27669 RLC 57233 b

1    phencyclidine or any of the salts, isomers and salts of
2    isomers of phencyclidine (PCP), or an analog thereof;
3        (10.5) 30 grams or more of any substance containing
4    ketamine or any of the salts, isomers and salts of isomers
5    of ketamine, or an analog thereof;
6        (10.6) 100 grams or more of any substance containing
7    hydrocodone, or any of the salts, isomers and salts of
8    isomers of hydrocodone, or an analog thereof;
9        (10.7) (blank);
10        (10.8) 100 grams or more of any substance containing
11    dihydrocodeine, or any of the salts, isomers and salts of
12    isomers of dihydrocodeine, or an analog thereof;
13        (10.9) 100 grams or more of any substance containing
14    oxycodone, or any of the salts, isomers and salts of
15    isomers of oxycodone, or an analog thereof;
16        (11) 200 grams or more of any substance containing any
17    other controlled substance classified in Schedules I or
18    II, or an analog thereof, which is not otherwise included
19    in this subsection.
20    (b) Any person sentenced with respect to violations of
21paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
22involving 100 grams or more of the controlled substance named
23therein, may in addition to the penalties provided therein, be
24fined an amount not more than $500,000 or the full street value
25of the controlled or counterfeit substance or controlled
26substance analog, whichever is greater. The term "street

 

 

SB2089- 33 -LRB103 27669 RLC 57233 b

1value" shall have the meaning ascribed in Section 110-5 of the
2Code of Criminal Procedure of 1963. Any person sentenced with
3respect to any other provision of subsection (a), may in
4addition to the penalties provided therein, be fined an amount
5not to exceed $500,000.
6    (b-1) Excluding violations of this Act when the controlled
7substance is fentanyl, any person sentenced to a term of
8imprisonment with respect to violations of Section 401, 401.1,
9405, 405.1, 405.2, or 407, when the substance containing the
10controlled substance contains any amount of fentanyl, 3 years
11shall be added to the term of imprisonment imposed by the
12court, and the maximum sentence for the offense shall be
13increased by 3 years.
14    (c) Any person who violates this Section with regard to
15the following amounts of controlled or counterfeit substances
16or controlled substance analogs, notwithstanding any of the
17provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
18to the contrary, is guilty of a Class 1 felony. The fine for
19violation of this subsection (c) shall not be more than
20$250,000:
21        (1) 1 gram or more but less than 15 grams of any
22    substance containing heroin, or an analog thereof;
23        (1.5) 1 gram or more but less than 15 grams of any
24    substance containing fentanyl, or an analog thereof;
25        (2) 1 gram or more but less than 15 grams of any
26    substance containing cocaine, or an analog thereof;

 

 

SB2089- 34 -LRB103 27669 RLC 57233 b

1        (2.5) 1 gram or more but less than 15 grams of any
2    substance containing xylazine, or an analog thereof;
3        (3) 10 grams or more but less than 15 grams of any
4    substance containing morphine, or an analog thereof;
5        (4) 50 grams or more but less than 200 grams of any
6    substance containing peyote, or an analog thereof;
7        (5) 50 grams or more but less than 200 grams of any
8    substance containing a derivative of barbituric acid or
9    any of the salts of a derivative of barbituric acid, or an
10    analog thereof;
11        (6) 50 grams or more but less than 200 grams of any
12    substance containing amphetamine or any salt of an optical
13    isomer of amphetamine, or an analog thereof;
14        (6.5) (blank);
15        (7)(i) 5 grams or more but less than 15 grams of any
16    substance containing lysergic acid diethylamide (LSD), or
17    an analog thereof, or (ii) more than 10 objects or more
18    than 10 segregated parts of an object or objects but less
19    than 15 objects or less than 15 segregated parts of an
20    object containing in them or having upon them any amount
21    of any substance containing lysergic acid diethylamide
22    (LSD), or an analog thereof;
23        (7.5)(i) 5 grams or more but less than 15 grams of any
24    substance listed in paragraph (1), (2), (2.1), (2.2), (3),
25    (14.1), (19), (20), (20.1), (21), (25), or (26) of
26    subsection (d) of Section 204, or an analog or derivative

 

 

SB2089- 35 -LRB103 27669 RLC 57233 b

1    thereof, or (ii) more than 10 pills, tablets, caplets,
2    capsules, or objects but less than 15 pills, tablets,
3    caplets, capsules, or objects containing in them or having
4    upon them any amount of any substance listed in paragraph
5    (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
6    (21), (25), or (26) of subsection (d) of Section 204, or an
7    analog or derivative thereof;
8        (8) 10 grams or more but less than 30 grams of any
9    substance containing pentazocine or any of the salts,
10    isomers and salts of isomers of pentazocine, or an analog
11    thereof;
12        (9) 10 grams or more but less than 30 grams of any
13    substance containing methaqualone or any of the salts,
14    isomers and salts of isomers of methaqualone, or an analog
15    thereof;
16        (10) 10 grams or more but less than 30 grams of any
17    substance containing phencyclidine or any of the salts,
18    isomers and salts of isomers of phencyclidine (PCP), or an
19    analog thereof;
20        (10.5) 10 grams or more but less than 30 grams of any
21    substance containing ketamine or any of the salts, isomers
22    and salts of isomers of ketamine, or an analog thereof;
23        (10.6) 50 grams or more but less than 100 grams of any
24    substance containing hydrocodone, or any of the salts,
25    isomers and salts of isomers of hydrocodone, or an analog
26    thereof;

 

 

SB2089- 36 -LRB103 27669 RLC 57233 b

1        (10.7) (blank);
2        (10.8) 50 grams or more but less than 100 grams of any
3    substance containing dihydrocodeine, or any of the salts,
4    isomers and salts of isomers of dihydrocodeine, or an
5    analog thereof;
6        (10.9) 50 grams or more but less than 100 grams of any
7    substance containing oxycodone, or any of the salts,
8    isomers and salts of isomers of oxycodone, or an analog
9    thereof;
10        (11) 50 grams or more but less than 200 grams of any
11    substance containing a substance classified in Schedules I
12    or II, or an analog thereof, which is not otherwise
13    included in this subsection.
14    (c-5) (Blank).
15    (d) Any person who violates this Section with regard to
16any other amount of a controlled or counterfeit substance
17containing dihydrocodeine or classified in Schedules I or II,
18or an analog thereof, which is (i) a narcotic drug, (ii)
19lysergic acid diethylamide (LSD) or an analog thereof, (iii)
20any substance containing amphetamine or fentanyl or xylazine
21or any salt or optical isomer of amphetamine or fentanyl or
22xylazine, or an analog thereof, or (iv) any substance
23containing N-Benzylpiperazine (BZP) or any salt or optical
24isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
25guilty of a Class 2 felony. The fine for violation of this
26subsection (d) shall not be more than $200,000.

 

 

SB2089- 37 -LRB103 27669 RLC 57233 b

1    (d-5) (Blank).
2    (e) Any person who violates this Section with regard to
3any other amount of a controlled substance other than
4methamphetamine or counterfeit substance classified in
5Schedule I or II, or an analog thereof, which substance is not
6included under subsection (d) of this Section, is guilty of a
7Class 3 felony. The fine for violation of this subsection (e)
8shall not be more than $150,000.
9    (f) Any person who violates this Section with regard to
10any other amount of a controlled or counterfeit substance
11classified in Schedule III is guilty of a Class 3 felony. The
12fine for violation of this subsection (f) shall not be more
13than $125,000.
14    (g) Any person who violates this Section with regard to
15any other amount of a controlled or counterfeit substance
16classified in Schedule IV is guilty of a Class 3 felony. The
17fine for violation of this subsection (g) shall not be more
18than $100,000.
19    (h) Any person who violates this Section with regard to
20any other amount of a controlled or counterfeit substance
21classified in Schedule V is guilty of a Class 3 felony. The
22fine for violation of this subsection (h) shall not be more
23than $75,000.
24    (i) This Section does not apply to the manufacture,
25possession or distribution of a substance in conformance with
26the provisions of an approved new drug application or an

 

 

SB2089- 38 -LRB103 27669 RLC 57233 b

1exemption for investigational use within the meaning of
2Section 505 of the Federal Food, Drug and Cosmetic Act.
3    (j) (Blank).
4(Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17;
5100-368, eff. 1-1-18.)